Socio Today
Congenital Heart Disease (CHD), known locally in Indonesia as Penyakit Jantung Bawaan (PJB), remains one of the most significant challenges in pediatric medicine, characterized by structural abnormalities of the heart that develop before birth. While the precise etiology of these malformations often remains elusive to medical science, healthcare experts emphasize that identifying and mitigating specific risk factors during pregnancy is the most effective strategy for reducing the incidence of this condition. According to Dr. Rizky Adriansyah, MKed, a pediatric specialist and Chairman of the Cardiology Coordination Staff Unit of the Indonesian Pediatric Society (IDAI), the complexity of CHD lies in its multifactorial nature, where environmental, nutritional, and medicinal factors intersect during the delicate stages of fetal development.
During a comprehensive webinar hosted in mid-February 2023, Dr. Rizky highlighted that although a direct cause-and-effect relationship is difficult to establish in every individual case, three primary risk factors have gained significant prominence in recent medical literature. These include maternal infections such as rubella, a deficiency in folic acid, and the consumption of certain medications—specifically anti-seizure drugs—during pregnancy. These factors can disrupt the intricate process of cardiogenesis, the stage where the fetal heart forms and begins to function. By addressing these factors through proactive prenatal care, the medical community hopes to lower the burden of CHD in a country where the condition accounts for a staggering percentage of early childhood mortality.
The Landscape of Congenital Heart Disease in Indonesia
The statistical reality of CHD in Indonesia paints a sobering picture of the public health landscape. Data from 2017 indicates that CHD is the second largest contributor to neonatal mortality in the country, accounting for approximately 17 percent of deaths during the first 28 days of life, surpassed only by complications related to prematurity. This high mortality rate is mirrored by global statistics provided by the World Health Organization (WHO), which estimates that one out of every 100 newborns suffers from some form of CHD. Within this group, approximately 25 percent are diagnosed with "critical" CHD, requiring surgical intervention or specialized medical care within the first year—and often the first days—of life.
In the Indonesian context, the challenge is compounded by a significant treatment gap. Dr. Rizky noted that currently, less than 50 percent of CHD cases in the country receive adequate medical or surgical handling. This disparity is attributed to a combination of systemic hurdles, including limited access to specialized cardiac centers, a shortage of pediatric cardiologists and cardiovascular surgeons, and a lack of advanced diagnostic equipment in remote regions. Furthermore, a general lack of public awareness often leads to delayed diagnosis, where children are only brought to medical attention after their condition has reached a terminal or irreversible stage.
Identifying Key Risk Factors and Misconceptions
One of the primary goals of the Indonesian Pediatric Society is to educate the public on the modifiable risks associated with CHD. While lifestyle choices like smoking and alcohol consumption have long been recognized as detrimental to fetal health, the medical community has observed that many cases of CHD occur even in the absence of these habits. This underscores the importance of focusing on less obvious risks, such as maternal nutrition and viral prevention.
The role of the rubella virus is particularly critical. If a woman contracts rubella during the first trimester of pregnancy, the virus can cross the placenta and interfere with the development of the fetal heart, eyes, and ears, a condition known as Congenital Rubella Syndrome (CRS). Similarly, folic acid is essential for DNA synthesis and cell growth; a deficiency in this B-vitamin during the early weeks of pregnancy—often before a woman even knows she is pregnant—can lead to neural tube defects and heart malformations.
Furthermore, the use of certain medications for chronic conditions, such as epilepsy or psychiatric disorders, must be carefully managed by healthcare providers. Some anti-seizure medications are known teratogens, meaning they can cause birth defects. For women of childbearing age with these conditions, pre-conception counseling is vital to balance the mother’s health needs with the safety of a potential pregnancy.
The Chronology of Prevention: From Pre-Conception to Birth
The window for preventing CHD is relatively narrow and occurs largely before a child is even born. Dr. Rizky emphasized that once a baby is born with a heart defect, the opportunity for "prevention" has passed, and the focus must shift entirely to "management" and "intervention." Therefore, the chronology of prevention must begin well before the third trimester.
- Pre-Conception Vaccination: Ensuring that women are immunized against rubella through the MR (Measles-Rubella) or MMR (Measles-Mumps-Rubella) vaccine is a foundational step. Public health initiatives in Indonesia have sought to increase vaccine coverage to create a "herd immunity" effect that protects pregnant women from outbreaks.
- Early Nutritional Intervention: Folic acid supplementation is most effective when started at least one month before conception and continued through the first trimester. This requires a shift in public health strategy toward educating all women of reproductive age, not just those who are currently pregnant.
- Routine Prenatal Screening: Regular check-ups allow for the monitoring of maternal health and the early identification of potential complications. While fetal echocardiography can sometimes detect CHD in utero, it requires specialized equipment and expertise that are not yet universally available in all Indonesian provinces.
Diagnostic Breakthroughs and Simplified Screening
Because many cases of CHD are not prevented, the secondary line of defense is early and accurate diagnosis. In Indonesia, the delay in diagnosis is a primary factor in high mortality rates. Many infants with critical CHD appear healthy at birth but deteriorate rapidly within the first 24 to 48 hours as the fetal circulatory pathways (such as the ductus arteriosus) begin to close.
To combat this, the medical community is advocating for the widespread adoption of pulse oximetry screening. This is a non-invasive, fast, and cost-effective test that measures the oxygen saturation in a newborn’s blood. By placing sensors on the baby’s right hand and either foot, healthcare providers can detect "silent" heart defects that do not present with obvious symptoms like cyanosis (bluish skin).
Dr. Rizky highlighted that this screening can be performed in less than five minutes by midwives (bidan) or general practitioners. If the oxygen levels are low or if there is a significant discrepancy between the hand and foot readings, it serves as a red flag for CHD, prompting an immediate referral to a specialist for an echocardiogram. Additionally, the use of a simple stethoscope remains a vital tool; the presence of a "murmur" or unusual heart sound should always trigger further investigation.
Clinical Symptoms and Parental Vigilance
Parents play a crucial role in the early detection of CHD, especially for non-critical cases that may manifest symptoms more slowly. One of the most common signs of a heart defect in infants is poor weight gain, often referred to as "failure to thrive." Because the heart has to work harder to pump blood, the infant burns more calories and may become easily fatigued during feeding. Other symptoms include rapid breathing, excessive sweating (especially during feeding), and a persistent cough or respiratory infections.
For more severe cases, symptoms appear almost immediately. Critical CHD is often identified in the first week of life when the infant may show signs of lethargy, cold extremities, or a grayish skin tone. Dr. Rizky pointed out that educational resources are becoming increasingly accessible to help parents recognize these signs. The YouTube channel "Sehatkan Jantung Anak Indonesia" serves as a digital repository for such information, providing tutorials on what to look for and how to navigate the healthcare system.
Broader Implications and the Path Forward
The high incidence of CHD and the low rate of successful intervention have profound implications for Indonesia’s socio-economic development. Treating CHD is expensive, often requiring multiple surgeries, long-term medication, and frequent hospitalizations. This places a heavy burden on the National Health Insurance (BPJS Kesehatan) and on the families themselves, who may face lost wages and emotional distress.
Analysis of the current situation suggests that Indonesia needs a multi-pronged approach to improve outcomes for children with CHD. First, there must be a continued investment in the "upstream" of healthcare—prevention through vaccination and nutrition. Second, the "midstream" requires the standardization of newborn screening across all birthing facilities, ensuring that pulse oximetry becomes a mandatory part of postnatal care. Finally, the "downstream" necessitates the decentralization of cardiac care. Currently, many of the most advanced cardiac procedures are concentrated in Jakarta or other major cities on Java, leaving families in the outer islands at a significant disadvantage.
The IDAI’s push for increased awareness among primary health workers, such as midwives and village health cadres, is a step in the right direction. By empowering those at the frontline of maternal and child health, the medical community can ensure that fewer cases of CHD go unnoticed.
In conclusion, while the exact cause of congenital heart disease may remain a mystery in many cases, the path toward reducing its impact is clear. Through a combination of maternal vaccination, proper nutrition, early screening, and improved medical infrastructure, Indonesia can begin to close the gap in CHD care. The goal is not only to save lives in the immediate neonatal period but to ensure that every child born with a heart defect has the opportunity to lead a healthy, productive life. As Dr. Rizky and his colleagues at the IDAI continue their advocacy, the hope is that CHD will move from being a leading cause of death to a manageable condition through the power of early detection and specialized care.
